TransCode Therapeutics, Inc.
Subrata Ghosh, MS, PhD has a strong background in biomedical research and drug discovery. Subrata is currently working as a Principal Scientist at TransCode Therapeutics, Inc. In their previous role as a Senior Scientist at Aviceda Therapeutics, they developed glyco-immune therapeutics inhibiting glycol-immune checkpoint receptors, focusing on NK cells, T cells, and monocytes. Subrata also established in vitro and ex vivo assays to investigate target biology, therapeutic development, and translational/biomarker strategy.
Prior to this, Ghosh worked as a Research Scientist I at Charles River Laboratories, where they led the development of preclinical evaluation methods for investigational immuno-modulatory drugs. Subrata was responsible for multiple assays, including flow cytometry-based immunophenotyping and receptor occupancy analysis. Subrata also supervised the assessment of immunotherapy targeting immune-checkpoint blockade in a team of immunology safety assessment scientists.
Ghosh has also held postdoctoral positions at UNC Lineberger Comprehensive Cancer Center and Boston University School of Medicine, where they focused on cancer biology. Subrata has experience in cell biology as an Instructor at Harvard Medical School and Massachusetts General Hospital. In addition, Ghosh worked as a Lead Scientist at Connexios Life Sciences, a drug discovery biotech company. In this role, they developed anti-diabetic molecules through cell-based assays and managed a biochemical/biological analytics group.
Throughout their career, Ghosh has demonstrated strong leadership and mentoring skills, as well as proficiency in various experimental techniques. Subrata has published and presented their research findings in reputable scientific conferences and journals.
Subrata Ghosh, MS, PhD has a Bachelor of Science (BS-Hons) degree in Chemistry from the University of Calcutta. Subrata then pursued a Master of Science (MS) degree in Biochemistry from the same university. Subsequently, they earned a Doctor of Philosophy (Ph.D.) in Biochemistry from the University of Calcutta as well.
This person is not in any teams
TransCode Therapeutics, Inc.
TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. Our lead therapeutic candidate, that we believe has blockbuster potential, targets an RNA molecule which has been shown to be the driver of metastatic disease across multiple tumor typesand has been validated pre-clinically in our lab at MGH. Our initial FIH clinical study, for which an eIND filing is planned for Q1 of 2022, is intended to provide positive proof-of-mechanism for the TTX platform.